Inhibitory effects of aripiprazole on interferon-γ-induced microglial activation via intracellular Ca2+ regulation in vitro

Journal of Neurochemistry

Volumn 106, Issue 2, 2008, Pages 815-825

  Kato, Takahiro ^a   Mizoguchi, Yoshito ^a   Monji, Akira ^a   Horikawa, Hideki ^a   Suzuki, Satoshi O ^a   Seki, Yoshihiro ^a   Iwaki, Toru ^a   Hashioka, Sadayuki ^a   Kanba, Shigenobu ^a  

^a KYUSHU UNIVERSITY   (Japan)

Author keywords

Atypical antipsychotic drug; Inflammatory cytokine; Intracellular Ca 2+ regulation; Microglia; Nitric oxide; Schizophrenia

Indexed keywords

ARIPIPRAZOLE; CALCIUM ION; GAMMA INTERFERON; NITRIC OXIDE; QUINPIROLE; TUMOR NECROSIS FACTOR ALPHA; CALCIUM; DOPAMINE 2 RECEPTOR; DOPAMINE RECEPTOR STIMULATING AGENT; NEUROLEPTIC AGENT; PIPERAZINE DERIVATIVE; QUINOLONE DERIVATIVE;

ANIMAL CELL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CELL ACTIVATION; CELL LEVEL; CELL STIMULATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG EFFICACY; DRUG MECHANISM; IMMUNOMODULATION; IN VITRO STUDY; MICROGLIA; MOUSE; NEWBORN; NONHUMAN; PRIORITY JOURNAL; PROTEIN SYNTHESIS INHIBITION; ANALYSIS OF VARIANCE; ANIMAL; BRAIN; CELL CULTURE; CELL SURVIVAL; CYTOLOGY; DOSE RESPONSE; DRUG EFFECT; DRUG INTERACTION; ENZYME LINKED IMMUNOSORBENT ASSAY; GENETICS; METABOLISM; METHODOLOGY; NERVE CELL; RAT; SPRAGUE DAWLEY RAT;

MURINAE;

ANALYSIS OF VARIANCE; ANIMALS; ANIMALS, NEWBORN; ANTIPSYCHOTIC AGENTS; BRAIN; CALCIUM; CELL SURVIVAL; CELLS, CULTURED; DOPAMINE AGONISTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; ENZYME-LINKED IMMUNOSORBENT ASSAY; INTERFERON TYPE II; MICE; MICROGLIA; NEURONS; NITRIC OXIDE; PIPERAZINES; QUINOLONES; QUINPIROLE; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, DOPAMINE D2; TUMOR NECROSIS FACTOR-ALPHA;

EID: 51649096464     PISSN: 00223042     EISSN: 14714159     Source Type: Journal    
DOI: 10.1111/j.1471-4159.2008.05435.x     Document Type: Article

References (71)

1. Akhondzadeh S., Tabatabaee M., Amini H., Ahmadi Abhari S. A., Abbasi S. H. and Behnam B. (2007) Celecoxib as adjunctive therapy in schizophrenia: a double-blind, randomized and placebo-controlled trial. Schizophr. Res. 90, 179-185.
2. Alexopoulos G. S., Streim J., Carpenter D. and Docherty J. P. (2004) Using antipsychotic agents in older patients. J. Clin. Psychiatry 65(Suppl 2), 5-104.
3. Baumann P., Hiemke C., Ulrich S. et al. and Arbeitsge-meinschaft fur neuropsychopharmakologie und p. (2004) The AGNP-TDM expert group consensus guidelines: therapeutic drug monitoring in psychiatry. Pharmacopsychiatry 37, 243-265.
4. Bayer T. A., Buslei R., Havas L. and Falkai P. (1999) Evidence for activation of microglia in patients with psychiatric illnesses. Neurosci. Lett. 271, 126-128.
5. Bernstein H. G., Bogerts B. and Keilhoff G. (2005) The many faces of nitric oxide in schizophrenia. A review. Schizophr Res. 78, 69-86.
6. Bian Q., Kato T., Monji A., Hashioka S., Mizoguchi Y., Horikawa H. and Kanba S. (2008) The effect of atypical antipsychotics, perospirone, ziprasidone and quetiapine on microglial activation induced by interferon-gamma. Prog. Neuropsychopharmacol. Biol. Psychiatry 32, 42-48.
7. Bruins Slot L. A., De Vries L., Newman-Tancredi A. and Cussac D. (2006) Differential profile of antipsychotics at serotonin 5-HT1A and dopamine D2S receptors coupled to extracellular signal-regulated kinase. Eur J. Pharmacol. 534, 63-70.
8. Buntinx M., Moreels M., Vandenabeele F., Lambrichts I., Raus J., Steels P., Stinissen P. and Ameloot M. (2004) Cytokine-induced cell death in human oligodendroglial cell lines: I. Synergistic effects of IFN- gamma and TNF-alpha on apoptosis. J. Neurosci. Res. 76, 834-845.
9. Burris K. D., Molski T. F., Xu C., Ryan E., Tottori K., Kikuchi T., Yocca F. D. and Molinoff P. B. (2002) Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors. J. Pharmacol. Exp. Ther. 302, 381-389.
10. Cardenas A., Moro M. A., Hurtado O., Leza J. C. and Lizasoain I. (2005) Dual role of nitric oxide in adult neurogenesis. Brain Res. Brain Res. Rev. 50, 1-6.
11. Cazzullo C. L., Sacchetti E., Galluzzo A., Panariello A., Colombo F., Zagliani A. and Clerici M. (2001) Cytokine profiles in drug-naive schizophrenic patients. Schizophr. Res. 47, 293-298.
12. Cazzullo C. L., Sacchetti E., Galluzzo A. et al. (2002) Cytokine profiles in schizophrenic patients treated with risperidone: a 3-month follow-up study. Prog. Neuropsychopharmacol. Biol. Psychiatry 26, 33-39.
13. Chew M. L., Mulsant B. H., Pollock B. G., Lehman M. E., Greenspan A., Kirshner M. A., Bies R. R., Kapur S. and Gharabawi G. (2006) A model of anticholinergic activity of atypical antipsychotic medications. Schizophr. Res. 88, 63-72.
14. Councill J. H., Tucker E. S., Haskell G. T., Maynard T. M., Meechan D. W., Hamer R. M., Lieberman J. A. and LaMantia A. S. (2006) Limited influence of olanzapine on adult forebrain neural precursors in vitro. Neuroscience 140, 111-122.
15. Davis K. L., Stewart D. G., Friedman J. I., Buchsbaum M., Harvey P. D., Hof P. R., Buxbaum J. and Haroutunian V. (2003) White matter changes in schizophrenia: evidence for myelin-related dysfunction. Arch. Gen. Psychiatry 60, 443-456.
16. Drzyzga L., Obuchowicz E., Marcinowska A. and Herman Z. S. (2006) Cytokines in schizophrenia and the effects of antipsychotic drugs. Brain Behav. Immun. 20, 532-545.
17. Farber K., Pannasch U. and Kettenmann H. (2005) Dopamine and noradrenaline control distinct functions in rodent microglial cells. Mol. Cell. Neurosci. 29, 128-138.
18. Franciosi S., Choi H. B., Kim S. U. and McLarnon J. G. (2002) Interferon-gamma acutely induces calcium influx in human microglia. J. Neurosci. Res. 69, 607-613.
19. Grynkiewicz G., Poenie M. and Tsien R. Y. (1985) A new generation of Ca2+ indicators with greatly improved fluorescence properties. J. Biol. Chem. 260, 3440-3450.
20. Hakak Y., Walker J. R., Li C., Wong W. H., Davis K. L., Buxbaum J. D., Haroutunian V. and Fienberg A. A. (2001) Genome-wide expression analysis reveals dysregulation of myelination-related genes in chronic schizophrenia. Proc. Natl Acad. Sci. USA 98, 4746-4751.
21. Halim N. D., Weickert C. S., McClintock B. W., Weinberger D. R. and Lipska B. K. (2004) Effects of chronic haloperidol and clozapine treatment on neurogenesis in the adult rat hippocampus. Neuropsychopharmacology 29, 1063-1069.
22. Hoffmann A., Kann O., Ohlemeyer C., Hanisch U. K. and Kettenmann H. (2003) Elevation of basal intracellular calcium as a central element in the activation of brain macrophages (microglia): suppression of receptor-evoked calcium signaling and control of release function. J. Neurosci. 23, 4410-4419.
23. Iosif R. E., Ekdahl C. T., Ahlenius H., Pronk C. J., Bonde S., Kokaia Z., Jacobsen S. E. and Lindvall O. (2006) Tumor necrosis factor receptor 1 is a negative regulator of progenitor proliferation in adult hippocampal neurogenesis. J. Neurosci. 26, 9703-9712.
24. Kane J. M., Crandall D. T., Marcus R. N., Eudicone J., Pikalov C. and Wh S. (2007) Symptomatic remission in schizophrenia patients treated with aripiprazole or haloperidol for up to 52 weeks. Schizophr. Res. 95, 143-150.
25. Kaneko N., Kudo K., Mabuchi T., Takemoto K., Fujimaki K., Wati H., Iguchi H., Tezuka H. and Kanba S. (2006) Suppression of cell proliferation by interferon-alpha through interleukin-1 production in adult rat dentate gyrus. Neuropsychopharmacology 31, 2619-2626.
26. Kanzawa T., Sawada M., Kato K., Yamamoto K., Mori H. and Tanaka R. (2000) Differentiated regulation of allo-antigen presentation by different types of murine microglial cell lines. J. Neurosci. Res. 62, 383-388.
27. Kapur S. and Mamo D. (2003) Half a century of antipsychotics and still a central role for dopamine D2 receptors. Prog. Neuropsychopharmacol. Biol. Psychiatry 27, 1081-1090.
28. Kato T., Monji A., Hashioka S. and Kanba S. (2007) Risperidone significantly inhibits interferon-gamma-induced microglial activation in vitro. Schizophr. Res. 92, 108-115.
29. Kawanokuchi J., Mizuno T., Takeuchi H., Kato H., Wang J., Mitsuma N. and Suzumura A. (2006) Production of interferon-gamma by microglia. Mult. Scler. 12, 558-564.
30. Kim H. S., Whang S. Y., Woo M. S., Park J. S., Kim W. K. and Han I. O. (2004) Sodium butyrate suppresses interferon-gamma-, but not lipopolysaccharide-mediated induction of nitric oxide and tumor necrosis factor-alpha in microglia. J. Neuroimmunol. 151, 85-93.
31. Labuzek K., Kowalski J., Gabryel B. and Herman Z. S. (2005) Chlorpromazine and loxapine reduce interleukin-1beta and interleukin-2 release by rat mixed glial and microglial cell cultures. Eur. Neuropsychopharmacol. 15, 23-30.
32. Lemmer K., Ahnert-Hilger G., Hopfner M., Hoegerle S., Faiss S., Grabowski P., Jockers-Scherubl M., Riecken E. O., Zeitz M. and Scherubl H. (2002) Expression of dopamine receptors and transporter in neuroendocrine gastrointestinal tumor cells. Life Sci. 71, 667-678.
33. J., Baud O., Vartanian T., Volpe J. J. and Rosenberg P. A. (2005) Peroxynitrite generated by inducible nitric oxide synthase and NADPH oxidase mediates microglial toxicity to oligodendrocytes. Proc. Natl Acad. Sci. USA 102, 9936-9941.
34. Lidow M. S. (2003) Calcium signaling dysfunction in schizophrenia: a unifying approach. Brain Res. Brain Res. Rev. 43, 70-84.
35. Lieberman J. A. (1999) Is schizophrenia a neurodegenerative disorder? A clinical and neurobiological perspective Biol. Psychiatry 46, 729-739.
36. Lieberman J. A., Tollefson G. D., Charles C. et al. (2005) Antipsychotic drug effects on brain morphology in first-episode psychosis. Arch. Gen Psychiatry 62, 361-370.
37. Lin A., Kenis G., Bignotti S., Tura G. J., De Jong R., Bosmans E., Pioli R., Altamura C., Scharpe S. and Maes M. (1998) The inflammatory response system in treatment-resistant schizophrenia: increased serum interleukin-6. Schizophr. Res. 32, 9-15.
38. Lu X. H. and Dwyer D. S. (2005) Second-generation antipsychotic drugs, olanzapine, quetiapine, and clozapine enhance neurite outgrowth in PC12 cells via PI3K/AKT, ERK, and pertussis toxin- sensitive pathways. J. Mol. Neurosci. 27, 43-64.
39. Lu L. X., Guo S. Q., Chen W., Li Q., Cheng J. and Guo J. H. (2004) Effect of clozapine and risperidone on serum cytokine levels in patients with first-episode paranoid schizophrenia. Di Yi Jun Yi Da Xue Xue Bao 24, 1251-1254.
40. Mahe C., Loetscher E., Dev K. K., Bobirnac I., Otten U. and Schoeffter P. (2005) Serotonin 5-HT7 receptors coupled to induction of interleukin-6 in human microglial MC-3 cells. Neuropharmacology 49, 40-47.
41. McGeer P. L., Kawamata T., Walker D. G., Akiyama H., Tooyama I. and McGeer E. G. (1993) Microglia in degenerative neurological disease. Glia 7, 84-92.
42. Merrill J. E., Ignarro L. J., Sherman M. P., Melinek J. and Lane T. E. (1993) Microglial cell cytotoxicity ofoligodendrocytes is mediated through nitric oxide. J. Immunol. 151, 2132-2141.
43. Miyamoto S., Duncan G. E., Marx C. E. and Lieberman J. A. (2005) Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs. Mol. Psychiatry 10, 79-104.
44. Miyaoka T., Yasukawa R., Yasuda H., Hayashida M., Inagaki T. and Horiguchi J. (2007) Possible antipsychotic effects of minocycline in patients with schizophrenia. Prog. Neuropsychopharmacol. Biol. Psychiatry 31, 304-307.
45. Mizoguchi Y., Monji A. and Nabekura J. (2002) Brain-derived neurotrophic factor induces long-lasting Ca2+-activated K+ currents in rat visual cortex neurons. Eur. J. Neurosci. 16, 1417-1424.
46. Monje M. L., Toda H. and Palmer T. D. (2003) Inflammatory blockade restores adult hippocampal neurogenesis. Science 302, 1760-1765.
47. Nikodemova M., Duncan I. D. and Watters J. J. (2006) Minocycline exerts inhibitory effects on multiple mitogen-activated protein kinases and IkappaBalpha degradation in a stimulus-specific manner in microglia. J. Neurochem. 96, 314-323.
48. Park J. S., Woo M. S., Kim S. Y., Kim W. K. and Kim H. S. (2005) Repression of interferon-gamma-induced inducible nitric oxide synthase (iNOS) gene expression in microglia by sodium butyrate is mediated through specific inhibition of ERK signaling pathways. J. Neuroimmunol. 168, 56-64.
49. Pocock J. M. and Kettenmann H. (2007) Neurotransmitter receptors on microglia. Trends Neurosci. 30, 527-535.
50. Potkin S. G., Saha A. R., Kujawa M. J., Carson W. H., Ali M., Stock E., Stringfellow J., Ingenito G. and Marder S. R. (2003) Aripiprazole, an antipsychotic with a novel mechanism ofaction, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder. Arch. Gen. Psychiatry 60, 681-690.
51. Radewicz K., Garey L. J., Gentleman S. M. and Reynolds R. (2000) Increase in HLA-DR immunoreactive microglia in frontal and temporal cortex of chronic schizophrenics. J. Neuropathol. Exp. Neurol. 59, 137-150.
52. Reif A., Fritzen S., Finger M., Strobel A., Lauer M., Schmitt A. and Lesch K. P. (2006) Neural stem cell proliferation is decreased in schizophrenia, but not in depression. Mol. Psychiatry 11, 514-522.
53. Rothermundt M., Arolt V. and Bayer T. A. (2001) Review of immunological and immunopathological findings in schizophrenia. Brain Behav. Immun. 15, 319-339.
54. Salisbury D. F., Kuroki N., Kasai K., Shenton M. E. and McCarley R. W. (2007) Progressive and interrelated functional and structural evidence of post-onset brain reduction in schizophrenia. Arch. Gen. Psychiatry 64, 521-529.
55. Sawada M., Imai F., Suzuki H., Hayakawa M., Kanno T. and NagatsuT. (1998) Brain-specific gene expression by immortalized microglial cell-mediated gene transfer in the mammalian brain. FEBS Lett. 433, 37-40.
56. Schlosser R. G., Nenadic I., Wagner G. et al. (2007) White matter abnormalities and brain activation in schizophrenia: a combined DTI and fMRI study. Schizophr. Res. 89, 1-11.
57. Schonwasser D. C., Marais R. M., Marshall C. J. and Parker P. J. (1998) Activation of the mitogen-activated protein kinase/extracellular signal-regulated kinase pathway by conventional, novel, and atypical protein kinase C isotypes. Mol. Cell. Biol. 18, 790-798.
58. Schwarz M. J., Muller N., Riedel M. and Ackenheil M. (2001a) The Th2-hypothesis of schizophrenia: a strategy to identify a subgroup of schizophrenia caused by immune mechanisms. Med. Hypotheses 56, 483-486.
59. Schwarz M. J., Chiang S., Muller N. and Ackenheil M. (2001b) T- helper-1 and T-helper-2 responses in psychiatric disorders. Brain Behav. Immun. 15, 340-370.
60. Shapiro D. A., Renock S., Arrington E., Chiodo L. A., Liu L. X., Sibley D. R., Roth B. L. and Mailman R. (2003) Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology. Neuropsychopharmacology 28, 1400-1411.
61. Steiner J., Mawrin C., Ziegeler A., BielauH., Ullrich O., Bernstein H. G. and Bogerts B. (2006) Distribution of HLA-DR-positive microglia in schizophrenia reflects impaired cerebral lateralization. Acta Neuropathol. 112, 305-316.
62. Steiner J., Bielau H., Brisch R., Danos P., Ullrich O., Mawrin C., Bernstein H. G. and Bogerts B. (2008) Immunological aspects in the neurobiology of suicide: elevated microglial density in schizophrenia and depression is associated with suicide. J. Psychiatr. Res. 42, 151-157.
63. Stoll G. and Jander S. (1999) The role of microglia and macrophages in the pathophysiology of the CNS. Prog. Neurobiol. 58, 233-247.
64. Takeuchi H., Wang J., Kawanokuchi J., Mitsuma N., Mizuno T. and Suzumura A. (2006) Interferon-gamma induces microglial-activation-induced cell death: a hypothetical mechanism of relapse and remission in multiple sclerosis. Neurobiol. Dis. 22, 33-39.
65. Tandon R., Marcus R. N., Stock E. G., Riera L. C., Kostic D., Pans M., McQuade R. D., Nyilas M., Iwamoto T. and Crandall D. T. (2006) A prospective, multicenter, randomized, parallel-group, open-label study of aripiprazole in the management of patients with schizophrenia or schizoaffective disorder in general psychiatric practice: Broad Effectiveness Trial With Aripiprazole (BETA). Schizophr. Res. 84, 77-89.
66. Taylor D., Atkinson J., Fischetti C., Sparshatt A. and Jones S. (2007) A prospective 6-month analysis of the naturalistic use of aripiprazole-factors predicting favourable outcome. Acta Psychiatr. Scand. 116, 461-466.
67. Uranova N. A., Vostrikov V. M., Orlovskaya D. D. and Rachmanova V. I. (2004) Oligodendroglial density in the prefrontal cortex in schizophrenia and mood disorders: a study from the Stanley Neuropathology Consortium. Schizophr. Res. 67, 269-275.
68. Urban J. D., Vargas G. A., von Zastrow M. and Mailman R. B. (2007) Aripiprazole has functionally selective actions at dopamine D2 receptor-mediated signaling pathways. Neuropsychopharmacology 32, 67-77.
69. Wakade C. G., Mahadik S. P., Waller J. L. and Chiu F. C. (2002) Atypical neuroleptics stimulate neurogenesis in adult rat brain. J. Neurosci. Res. 69, 72-79.
70. Wang H. D., Dunnavant F. D., Jarman T. and Deutch A. Y. (2004) Effects of antipsychotic drugs on neurogenesis in the forebrain of the adult rat. Neuropsychopharmacology 29, 1230-1238.
71. Zhang X. Y., Zhou D. F., Cao L. Y., Zhang P. Y., Wu G. Y. and Shen Y. C. (2004) Changes in serum interleukin-2, -6, and -8 levels before and during treatment with risperidone and haloperidol: relationship to outcome in schizophrenia. J. Clin. Psychiatry 65, 940-947.